Note 10 - Subsequent Events

9 Months Ended

Sep. 30, 2015

Notes to Financial Statements

Subsequent Events [Text Block]

10. Subsequent Events

The Company has evaluated all activity that occurred subsequent to quarter end but prior to issuance of the condensed consolidated financial statements for events or transactions that could require disclosure or that could impact the carrying value of assets or liabilities as of the balance sheet date. The Company completed patient enrollment in the first of two Phase 3 trials for vonapanitase in radiocephalic AVFs in October 2015. In the judgment of management, there were no other material events that impacted the unaudited condensed financial statements or disclosures.